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Association of symptoms and interval breast cancers in the
mammography-screening programme: population-based
matched cohort study
Deependra Singh1,2, Joonas Miettinen1, Stephen Duffy3, Nea Malila1,2, Janne Pitkäniemi1 and Ahti Anttila1
BACKGROUND: We assessed the association between symptoms reported at breast cancer screening visits and interval cancers
(ICs) in a prospective manner.
METHODS: This population-based matched cohort study uses data of the Finnish National Breast Cancer Screening Programme
that invites women aged 50–69 years old during 1992–2012. Subjects who attended screening with symptoms were matched with
asymptomatic reference cohorts based on age at screening visit, year of invitation, number of invited visits and municipality of
invitation. The primary outcome was ICs.
RESULTS: Women with a lump had a threefold (hazard ratio 3.7, 95% conﬁdence interval (CI) 3.0–4.6) risk of ICs and a higher risk
(hazard ratio 1.7, 95% CI 1.4 to 2.0) at the subsequent visit compared with those without a lump. The fatal interval cancer risk
increased by 0.39 per 1000 screens with a lump. The cumulative incidences of interval cancer increased within a month of a
mammography-negative visit with a lump and after about 6 months of the visit with retraction or nipple discharge.
CONCLUSION: Women with breast symptoms have a clearly increased risk of interval breast cancer after the screening visit. Our
ﬁndings indicate the need for different screening strategies in symptomatic women.
British Journal of Cancer (2018) 119:1428–1435; https://doi.org/10.1038/s41416-018-0308-2
BACKGROUND
Beyond the randomised trial environment, there is some
uncertainty as to the underlying incidence of breast cancer and
the rate of overdiagnosis in the screening population.1,2 Along
with screening performance,3–5 rates and proportions of interval
cancers (ICs) are important indicators for assessing the effective-
ness and quality of screening.2,6–8 The substantial proportion
(about a third) of incident breast cancer diagnosed outside the
mammography-screening programme9,10 likely indicates that
there is room for improvement in the detection capability of the
mammography-screening programme. Earlier observational stu-
dies7,11–15 have highlighted several reasons for the increased
proportion of ICs in the screening programme. However, in terms
of equity within the screening population, it is reasonable to aim
for similar interval cancer rates or at least similar proportions of
cancers arising as interval cases for the various heterogeneous
groups participating in the screening. Furthermore, options to
modify screening policies should be considered for high-risk
groups. A shorter screening interval may be justiﬁed, for instance,
if the interval cancer rate is signiﬁcantly high.
Based on the European Union (EU) guidelines, screening is
meant for unselected target population.7 Earlier studies from
Finland have indicated that a noticeable proportion (~ 2–3%) of
women have clinically signiﬁcant symptoms when they participate
in breast cancer screening.16,17 Most but not all symptomatic
women will have further assessments with ultrasound, additional
mammograms or other methods; if these return negative results,
the women return to the normal, biennial screening interval.
Studies on breast symptoms (such as a lump, retraction or nipple
discharge) indicate an increased risk of breast cancer16–19 at the
cost of rise in false-positive ﬁndings. The relations of symptoms
with interval breast cancers and screen-detected cancers (SDCs) at
the subsequent visit have never been studied.
We investigated whether women reporting breast symptoms at
screen are at a higher risk of developing subsequent breast
cancers (ICs and cancers diagnosed at the next screen) than those
without symptoms. To create foundations to modify the screening
policies in high-risk groups, we estimated the cumulative
incidence of ICs and fatal interval breast cancers, and compared
the respective incidences in women with and without symptoms.
The quality measures of screening mammography were compared
between visits among subjects with and without symptoms to
gather evidence for improving programme performance.
METHODS
Study design, data source and study population
Our matched cohort study design was based on the follow-up of
the ongoing Finnish National Breast Cancer Screening Programme
that began in 1987. Biennial screening visits made by women
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aged 50–69 years between 1991 and 2012 were selected. Three
registries, the Finnish Cancer Registry (1953–2014), the Mass
Screening Registry (1992–2012) and the Central Population
Registry (1992–2014) were used to extract information on the
study participants at the individual level. The Mass Screening
Registry was used to extract information on demographic,
symptomatic and screening procedure factors, including recalls
and referral data that have been shown to be valid and of high
quality. All individual visits were linked to the Finnish Cancer
Registry database to retrieve information on breast cancers
(screen-detected and ICs). This included histological ﬁndings and
potential death from incident breast cancer. The Population
Registry was used to identify possible dates of death or
emigration, and where applicable, the cause of death was
retrieved from Statistics Finland. Fig. 1 shows the ﬂow diagram
of the study design.
Exposure group (screening visits with symptoms)
The exposed group is deﬁned as visits by women with breast
symptoms (lump, retraction and nipple discharge) reported at a
given screening round. This group contained all visits with at least
one symptom reported. Different symptoms (lump, retraction,
nipple discharge) were analysed separately, which in technical
terms assumes that the ﬁrst occurrence of any symptom was
independent given the covariates. For example, if more than one
symptom was reported at a single visit then each symptom was
analysed separately. Here, the index visit meant any screening visit
with any given symptom.
Reference group (screening visits without symptoms)
The reference group is deﬁned as visits by women with no
reported breast symptoms in the screening history before the
index visit. The women from the reference group can later be the
part of the exposed group if symptoms are reported at future
screening visits. Thus, symptoms are time-dependent covariates.
Individual sets of reference visits for each symptom—altogether
three sets—were formed by matching.
Matching
The three exposed groups were frequency matched to the
reference groups by age at the screening visit (within 2 years),
year of invitation (2-year band), number of visits in the past and
municipality of invitation. Visits with symptoms were then
aggregated based on matching variables (and other covariates).
Each symptom stratum was matched to the viable controls
(reference visits) by random sampling. Random controls were
selected, based on the matching variables above, as many times
as the number of visits in each stratum of symptoms by the
replacement sampling method. Hence, a single control had the
possibility to be randomly selected more than once to the same
stratum. Based on our assumption of an effect size and required
power of 0.80, the exposed-to-reference-visits ratio was 1:1 for
lump and retraction, and 1:2 for nipple discharge.
Outcome assessment
ICs were deﬁned as breast cancers diagnosed in screened women
before the next screening visit or within a period equal to a
screening interval with (i) negative mammography at the index
visit (i.e., test negative); (ii) positive mammography at the index
visit, but negative further assessment (i.e., episode negative); and
(iii) positive further assessment but a date of diagnosis > 6 months
after mammography.2 SDCs were deﬁned as primary breast cancer
diagnosed among the screening attendees within 6 months
following an abnormal mammogram (test positive). The subse-
quent round SDCs were analysed following the index visits with or
without symptoms if the women attended the subsequent round.
Finnish national breast cancer screening program (FNBCSP)
Mass screening registry
(1992-2012)
Information on the
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screening process,
includes symptoms
information
Information on
cancers, screen-
detected and interval
cancers, and fatal
breast cancers
222848 visits
excluded because of
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on symptoms status Visits with symptoms
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Lump = 51333
Retraction = 40917
Nipple discharge = 9083
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(reference group)
No lump = 51332
No retraction = 40917
No nipple discharge = 18166
Matching*
Exposure group were frequency
matched to reference group
(visits without symptoms) by
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(1992-2014)
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Fig. 1 Flow diagram of study settings
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In addition, cancers were sub-grouped into in situ carcinomas and
non-localised breast cancers. Fatal cancers were deﬁned as those
breast cancers that resulted in death during follow-up.
Follow-up
The follow-up time started from the index visit in 1 January 1992
to 31 December 2012 and ended at the date of emigration or
death, upon diagnosis of interval cancer or at the end of the
follow-up—i.e., 31 December 2014—whichever occurred ﬁrst.
Cancer cases diagnosed among those screened up to 31
December 2012 and followed up to 31 December 2014 (for those
screened in 2011 and 2012) were divided into ICs and subsequent
SDCs using Finnish Cancer Registry data. Considering possible
delays in the diagnosis date after positive mammography ﬁndings,
a screening episode of 6-month intervals was used in the
deﬁnition of detection mode. Thus, the follow-up time for ICs
started at 7 months for episode negative visits and at 1 month for
test negative visits and ended at the date of the subsequent
screening visit at 23 months.
Statistical analysis
We compared breast cancer risk and the risk of breast cancer
death using Cox proportional hazard regression among women
with and without reported symptoms at the index screen.
Conﬁdence intervals were computed exactly from parameter
likelihoods. The analyses were adjusted for age at the screening
visit. We calculated the incidence rate of interval cancer between
the screens (from the index screen and the 6-month episode to
the subsequent screening visit) separately for test negatives and
episode negatives.
We also evaluated the programme characteristics using basic
statistics. A test sensitivity was estimated as the number of visits
with a positive mammography test and diagnosis of cancer at
screen divided by the sum of SDCs plus ICs diagnosed after
negative test results. Episode sensitivity was calculated as the
number of visits with a diagnosis of cancer in a full diagnostic
process in the screened population divided by all cancers
detected in a screening round among attenders. Similarly, the
positive predictive value (PPV) was assessed as the number of
visits with a positive mammography test and diagnosis of cancer
divided by the number of test positives. The negative predictive
value (NPV) was estimated as the number of visits with a negative
test result and no cancer diagnosed divided by the number of test
negatives. All statistical analyses were performed using R-3.4.0.
RESULTS
Over the study period of 21 years, a lump was reported at 51,333
visits and retraction at 40,917 visits. These visits were matched to
an equal number of asymptomatic visits. There were 9083 visits
with nipple discharge, and they were matched with double the
number of reference visits (i.e., 18,166 visits) without nipple
discharge. Detailed numbers of the potentially eligible and the
conﬁrmed eligible population included in the study are shown in
Fig. 1.
The mean age at a screening visit did not differ between visits
with and without symptoms (mean age 55.7 vs 56.1 years for visits
with and without a lump, respectively). Table 1 shows the
characteristics of the ﬁnal study cohort. About one in three
women who reported a lump or nipple discharge and one in eight
women who reported retraction were ﬁrst-time attendees. The
ﬁrst and subsequent attendee’s proportions were similar between
visits with and without symptoms. More than 80% of ICs and the
subsequent round’s SDCs, irrespective of reported symptoms
status, were not recalled for further assessment at the index visit.
Both the test and episode sensitivity of the mammography was
higher for visits with a lump or retraction compared with those
without such symptoms (82 and 75% vs 64 and 63% for a lump vs
no lump; 77 and 76% vs 67 and 66% for retraction vs no retraction;
Table 2). Likewise, the PPV of mammography was higher for
retraction and a lump, compared with those without these
symptoms. However, the speciﬁcity of mammography was clearly
lower for visits with a lump (88%) than those without (98%). Some
decrease in speciﬁcity was also seen for retraction and nipple
discharge.
Incidence of screen-detected and ICs, subsequent SDCs and fatal
ICs
In total, 1440 (2.8%) SDCs and 387 (0.7%) ICs (ICs) were diagnosed
in those who reported a lump compared with 174 (0.3%) SDCs and
103 (0.2%) ICs in those without a lump, respectively (Table 3). The
proportions of SDCs and ICs were higher also for retraction and
nipple discharge compared with those without these symptoms.
The age-adjusted risk of SDCs was signiﬁcantly higher in those
who reported a lump (adjusted hazard ratio 8.2, 95% CI 7.0–9.7),
retraction (adjusted hazard ratio 2.3, 95% CI 2.0–2.8) or nipple
discharge (adjusted hazard ratio 1.5, 95% CI 1.1–2.3) compared
with those without symptoms. In addition, the age-adjusted risk of
ICs was signiﬁcantly higher for a lump (adjusted hazard ratio 3.7,
95% CI 3.0–4.6), retraction (adjusted hazard ratio 1.5, 95% CI
1.1–1.9), and nipple discharge (adjusted hazard ratio 2.4, 95% CI
1.6–3.7) compared with those without these symptoms. The risk of
SDCs in the subsequent round was signiﬁcantly higher only after
visits with a lump compared with those without a lump (adjusted
hazard ratio 1.6, 95% CI 1.3–2.0). The risk of in situ interval
carcinomas or subsequent screen-detected carcinomas was also
higher in visits with a lump and nipple discharge compared with a
visit with no symptoms. The risk of non-localised interval breast
cancer as well as SDCs in the subsequent round were also greater
for all three symptoms in comparison with visits without
symptoms.
The age-adjusted risk of dying from breast cancer was
signiﬁcantly higher in those who reported a lump and were
diagnosed with invasive cancers (SDCs= adjusted hazard ratio 19,
95% CI 11–38; ICs= adjusted hazard ratio 2.0, 95% CI 1.1–3.4;
subsequent round cancers= adjusted hazard ratio 2.7, 95% CI
1.6–4.1) compared with those without a lump (Table 3). In
addition, the risk of dying was higher in those who reported
retraction and were diagnosed with SDCs (adjusted hazard ratio
6.3, 95% CI 2.8–16) compared with those without retraction. Only
a few deaths occurred during the follow-up in those who reported
nipple discharge.
Cumulative incidence of breast cancers during the screening
interval
The incidence of ICs after a visit with a lump or nipple discharge
increased rather rapidly after the visit in all the studied
progression types (Fig. 2 a–d). When using the cumulative
incidence of the asymptomatic over the whole interval as a
reference, the same level of ICs was reached in only about six
months after visits with a lump and 12 months after visits with
nipple discharge. Remarkably, in mammography-negative visits
with a lump, the cumulative incidence curve detached from the
no lump curve immediately after the ﬁrst month of visit, whereas
such a difference was not observed for the other symptom types.
DISCUSSION
In this population-based study with 21 years of screening (the
follow-up is restricted to 23 months, although the study period
was 21 years), we observed strong associations between
symptoms and breast cancer risks. Women reporting a lump at
a screening visit had a threefold risk of ICs compared with those
with no symptoms, also including subsequent SDCs. The
(cumulative) incidence of interval cancer was higher in those
who reported a lump irrespective of the mammography ﬁndings
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(test negatives or episode negatives) compared with those
without symptoms at the index visit. Likewise, retraction and
nipple discharge were signiﬁcantly associated with increased risks
of interval breast cancers. In absolute terms, per 1000 women who
attended and reported a lump, seven women were diagnosed
with invasive interval breast cancers, i.e., within 24 months
compared with about two cancers diagnosed without symptoms.
The fatal interval cancer risk increased by 0.39 per 1000 screens
with a lump.
Women with symptoms had a clearly increased ‘background’
risk of breast cancer; the conventional screening performance
measures—such as sensitivity, PPV and speciﬁcity—did not fully
assess this aspect. The cumulative incidence patterns as well as
the detection of cancers during the subsequent round provided
direct evidence of the need for risk-adjusted screening and a
better diagnostic work-up in the symptomatic women. The
diagnostic work-up could include developing better reading and
recall criteria in screening mammograms, a more detailed
Table 2 Performance quality measures of screening mammography in relation to symptoms status
Symptoms Screening episode Mammography test
Sensitivity % (95% CI) Sensitivity % (95% CI) PPV % (95% CI) NPV % (95% CI) Speciﬁcity % (95%CI)
Lump Yes 74 (71–78) 81 (80–83) 19 (19–20) 99 (99–99) 88 (88–88)
No 62 (56–68) 64 (58–70) 12 (11–13) 99 (99–99) 97 (97–97)
Retraction Yes 75 (72–79) 76 (73–80) 28 (26–29) 99 (99–99) 97 (96–97)
No 65 (59–70) 66 (60–72) 17 (16–19) 99 (99–99) 97 (97–98)
Nipple discharge Yes 55 (46–65) 62 (52–71) 8.1 (6.9–9.4) 99 (99–99) 91 (91–92)
No 66 (57–75) 70 (61–78) 15 (13–17) 99 (99–99) 97 (97–97)
PPV positive predictive value, NPV negative predictive value, CI conﬁdence interval
Table 1 Cohort characteristics
Characteristics Lump (n= 51,333) Retraction (n= 40,917) Nipple discharge*
Yes (%) No (%) Yes (%) No (%) Yes (%)
(n= 9083)
No (%)
(n= 18,166)
Age at index visit (mean, SD) 55.7 (4.6) 56.1 (4.5) 57.7 (4.9) 56.6 (4.8) 54.9 (4.6) 56.1 (4.7)
Attendance First attendance 18,305 (35) 17,954 (35) 5012 (12) 4959 (12) 2904 (32) 5643 (31)
Subsequent attendance 33,028 (64) 33,379 (65) 35,905 (87) 35,958 (87) 6179 (68) 12,523 (68)
Previous round
attendance
Yes 31,571 (61) 32,228 (62) 34,168 (83) 34,263 (83) 5842 (64) 12,069 (66)
No 19,762 (38) 19,105 (37) 6749 (16) 6654 (16) 3241 (35) 6097 (33)
Period of visit 1992–1997 15,478 (30) 15,520 (30) 0 0 1134 (12) 2298 (12)
1998–2002 7535 (14) 7493 (14) 3552 (8.7) 3552 (8.7) 1673 (18) 3316 (18)
2003–2007 11,791 (23) 11,804 (23) 12,996 (31) 13,190 (32) 2872 (31) 5671 (31)
2008–2012 16529 (32) 16,516 (32) 24,369 (59) 24,175 (59) 3404 (37) 6881 (37)
Recall (test positives)
Invasive cancers Screen-detected cancers 1440 (2.8) 174 (0.34) 461 (1.1) 192 (0.47) 66 (0.73) 83 (0.46)
Interval cancers 70 (0.14) 7 (0.01) 16 (0.04) 5 (0.01) 12 (0.13) 6 (0.03)
Subsequent screen at next
round
34 (0.07) 6 (0.01) 11 (0.03) 7 (0.02) 4 (0.04) 3 (0.01)
Fatal breast cancers Screen-detected cancers 215 (0.41) 11 (0.02) 38 (0.09) 6 (0.01) 4 (0.04) 2 (0.01)
Interval cancers 8 (0.01) 2 (0.01) 2 2 0 0
Subsequent screen at next
round
1 (0.01) 0 1 (0.01) 0 0 0
No recall (test negatives)
Invasive cancers Screen-detected cancers 0 0 0 0 0 0
Interval cancers 317 (0.62) 96 (0.19) 138 (0.34) 96 (0.23) 40 (0.44) 35 (0.19)
Subsequent screen at next
round
230 (0.45) 149 (0.29) 144 (0.35) 135 (0.33) 28 (0.31) 57 (0.31)
Fatal breast cancers Screen-detected cancers 0 0 0 0 0 0
Interval cancers 32 (0.06) 18 (0.03) 13 (0.03) 5 (0.01) 5 (0.05) 2 (0.01)
Subsequent screen at next
round
18 (0.03) 7 (0.01) 4 (0.01) 4 (0.01) 0 1 (0.01)
Values are numbers (percentage) unless stated otherwise
*For each visits with nipple discharge were matched with two visits without nipple discharge
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indication for biopsies in the further assessment, and early recall
for those with high-risk symptoms for whom the screening test or
further assessment proves negative.
Strengths and limitations of the study
To our knowledge, this is the ﬁrst population-based study to
analyse the association between symptoms and interval and fatal
breast cancers. Our study has several strengths. First, we included
all screening visits with symptoms from the start of the
mammography-screening programme (over 21 years) and com-
pared them with visits without symptoms. Since this was a
population-based service-screening programme, the selection bias
was minimal. Second, we could use validated prospectively
collected register data with no recall bias.20 Validation of the
cancer diagnosis (screen-detected and ICs) and death from cancer
using national and covering data sources (Finnish Cancer Registry
and Statistics Finland) and the use of unique personal identiﬁer for
individual-level linkage eliminates the possibility of selective
misclassiﬁcation. Third, we matched the symptomatic visits to
asymptomatic visits by possible confounding baseline character-
istics to minimise bias in the risk estimates. As a result, we found
no signiﬁcant difference in the background variables between
visits with and without symptoms. Finally, the programme process
and outcome indicator deﬁnitions used in this study adhere to
those deﬁned by WHO-IARC and mentioned in EU guidelines on
breast cancer screening and diagnosis,7,21 including the provision
of relevant information describing the performance and also
failures during the various steps of the screening process.
Our study also has potential limitations. The symptom informa-
tion was based on the women’s reporting in the past 2 or
6 months and a check by a radiographer at the visit. The
radiographer’s inspection is likely to be less comprehensive than a
full clinical examination. The collection of symptom information
is mainly done in order to support the interpretation of the
mammograms. However, in almost every case—if not all—the
radiographer or nurse examines the breast to conﬁrm
the presence of symptoms (mainly a lump and retraction) before
the mammography is performed. Thus, there are reasons to
consider the collected symptom information to be valid, albeit not
perfect. A second potential limitation is that our estimates could
have been confounded, because symptomatic women are more
likely to attend than asymptomatic women. However, because of
the high attendance rate in the Finnish mammography-screening
programme (84% among the invited, the highest among any
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existing mammography-screening programme), and as 97% of
attendees are asymptomatic, the attendance bias caused by
symptoms is likely to be small. Third, we did not use the
background incidence of breast cancer to estimate the interval
cancer rate in the absence of screening, but instead used a
detection method22 that takes into account cancers from the
screening programme; thus, estimates are sensitive to over-
diagnosis and lead time bias. Given the high coverage and
attendance rate in the Finnish screening programme, it was not
possible to ﬁnd a comparable non-screened group to estimate the
background incidence of breast cancer. In addition, there was no
possibility to estimate background incidence of breast cancer in
women with symptoms. We did not ﬁnd any difference in the PPV
of mammography, with and without symptoms, between the ﬁrst
and subsequent screening rounds (not shown in results); thus, the
lead time bias because of prevalent screens is negligible.
Furthermore, we used invasive breast cancers—and also
advanced and fatal breast cancers, which would be less affected
by overdiagnosis—to estimate the incidence rates and hazard
ratios. Only 5% of all carcinomas in those with symptoms were
in situ carcinomas.
Previous studies on the association between symptoms and the
risk of breast cancer are limited because of factors such as study
design, size, follow-up time and assessment of the possible
outcome measures of breast cancer. Nonetheless, a few studies
have found that the presence of a palpable lump is associated
with a higher risk of SDCs.18,19 We are not aware of any studies
that have assessed the relationship of symptoms with other
outcome measures.
Clinical and public health implications
Both the screening test and episode sensitivities tended to be
higher in symptomatic women compared with the asymptomatic.
Correspondingly, the screening speciﬁcity was lower in the
symptomatic women. Of note, particularly in women with a lump,
were the (episode) sensitivity losses in the further assessment during
the index visits. Moreover, higher interval cancer incidence within six
months after a negative mammography with a lump is a clear
concern for the programme. This indicates that further assessment is
needed more frequently (albeit with a potential loss of speciﬁcity),
and there needs to be highly stringent diagnostic evidence for a
decision not to carry out a full further assessment including a core
biopsy in these cases. As most visits (~ 97%) were asymptomatic, the
number of additional services would be rather small as well as the
improvement of programme’s overall performance and outcome.
But still, high-quality and clinically appropriate services are
important for women having symptoms at a screening visit. One
option is to recall all women with symptoms even if the
mammography result is negative, as practised in Norway (< 0.3%
of all those screened were recalled with symptoms).23 Doing this in
Finnish programme would signiﬁcantly lower the PPV of recall, as
2.5% of all screens had symptoms and only ~ 1 out of 10 sympto-
matic visits have been recalled.17
Taking into account the high incidence of advanced and fatal
interval breast cancers in symptomatic women, it is likely that
protection by biennial screening visit would clearly not be
sufﬁcient even after potential improvements in further assess-
ments. We are not aware of recommendations for surveillance or
follow-up of symptomatic women in the programme. Hence, we
recommend a shorter screening interval for the symptomatic
group so that the cumulative incidences of interval and fatal
interval cancer would possibly become more equitable. For two of
the studied symptoms (lump and nipple discharge), the interval
cancer incidence increased so rapidly that the ﬁrst follow-up visit
could take place very shortly after the index visit. Finally, taking
into account the probability of fatal screen-detected breast cancer
is higher in women with a symptom already at the index visit,
women need to be better informed about symptoms and made
aware that if a symptom occurs, it is not a good idea to wait until
the next invitation to the programme. Guidelines for further
assessment in patients presenting with symptoms before having a
scheduled invitation according to the programme—as developed
by National Health Service in the UK24—could be useful also in
other settings.
CONCLUDING REMARKS
Women with breast symptoms at visits within the population-
based breast cancer screening programme have a clearly
increased risk of breast cancer. The cumulative incidence of
invasive, advanced and fatal breast cancers, as well as the
detection of them at the next screen, provide direct evidence for
the need for risk-adjusted screening in symptomatic women—
e.g., tailoring the management procedures at index visits and
shortening the screening intervals for these women. This study
provides clear evidence to update and support the EU guidelines7
recommendation that ensures sufﬁcient attention being paid to
symptomatic details provided by women. Our ﬁndings therefore
have important implications for screening-aged women, radiolo-
gists, nurses and mammography-screening programmes overall.
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